TARGET AUDIENCE
This educational activity is intended for members of the hematology care team, including physicians, nurse practitioners, and PAs.

PROGRAM OVERVIEW
This dynamic and insightful webinar brings the patient voice to the forefront, highlighting the real-world impact of chronic immune thrombocytopenia (cITP) on quality of life (QOL) and health outcomes. This activity is designed to equip health care providers with practical strategies to enhance patient collaboration in treatment decision-making, offering actionable resources to support the process.

New and emerging therapeutic options for managing persistent/chronic ITP, providing in-depth clinical profiles of the latest advancements will be reviewed. Gain valuable insights into how to address your patients' most frequent concerns regarding these therapies, empowering you to better guide them through their treatment journey.

Upon completion of this activity, the learners should be able to:

• Demonstrate understanding of the impact of cITP on patients
• Outline for a patient the benefits and risks of current treatment approaches for cITP
• Address common patient concerns regarding emerging cITP treatment options

INTRODUCTION
Caroline Kruse
President and CEO
Platelet Disorder Support Association – PDSA
Cleveland, OH
USA

MODERATOR
Nichola Cooper, MA, MBBS, FRCP, FRCPath, MD
Professor of Immune Hematology
Department of Immunology and Inflammation - Faculty of Medicine
Imperial College Healthcare
NHS Trust
London, England
UK

FACULTY AND PLANNING COMMITTEE
David J. Kuter, MD, DPhil
Chief of Hematology
Massachusetts General Hospital
Professor of Medicine
Harvard Medical School
Boston, MA
USA

Terry Gernsheimer, MD
Professor of Hematology (Emerita)
University of Washington, Seattle
Seattle Cancer Care Alliance
Seattle, WA
USA

Stephanie Sanford, APRN
Hematology/Oncology Nurse Practitioner
North Shore Cancer Center
Massachusetts General Hospital
Boston, MA
USA

Brenda Shy
Person living with cITP
Albany, GA
USA

In support of improving patient care, this activity has been planned and implemented by The France Foundation (TFF), the International Society on Thrombosis and Haemostasis (ISTH), and the Platelet Disorder Support Association (PDSA). The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.

Physicians: The France Foundation designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: The France Foundation designates this activity for 1.0 nursing contact hours.

Physician Assistants: The France Foundation has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit(s). PAs should only claim credit commensurate with the extent of their participation.

Pharmacists: This knowledge-based (or, rarely, application-based) activity, UAN JA0007204-9999-24-095-H01-P, qualifies for 1.0 contact hours (0.10 CEUs) of continuing pharmacy education credit. Please submit all evaluations and credit requests no later than 30 days after you complete this activity to ensure your credit fulfillment, as CE credit cannot be awarded past 60 days from the activity date. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).

DISCLOSURE POLICY
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, The France Foundation (TFF), the International Society on Thrombosis and Haemostasis (ISTH), and the Platelet Disorder Support Association (PDSA) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial entity. TFF, ISTH, and PDSA resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF, ISTH, and PDSA seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF, ISTH, and PDSA are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Planning committee members, faculty, reviewers, and activity staff have disclosed the following relevant financial relationships. All relevant financial relationships listed have been mitigated.

TFF, ISTH, and PDSA require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF, ISTH, and PDSA do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information. .

This activity is supported by an independent medical educational grant from Novartis and SOBI.

The France Foundation, ISTH, and PDSA present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation, ISTH, PDSA, and the commercial supporter(s) assume no liability for the information herein.